BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:testosterone undecanoate readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of testosterone undecanoate\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04049331-6672@assetmemo.bio
DTSTAMP:20261121T005343Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:testosterone undecanoate: Phase 2 readout est. (NCT04049331)
DESCRIPTION:testosterone undecanoate\, phase 2\, Hypogonadism.\nStudy: Test
 osterone Replacement in Male Cancer Survivors With Fatigue and Low Testost
 erone\nEstimated primary completion: 30 January 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/testosterone-undecanoate#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04049331
URL:https://assetmemo.bio/drug/testosterone-undecanoate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04798469-6672@assetmemo.bio
DTSTAMP:20261121T005343Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:testosterone undecanoate: Phase 2 readout est. (NCT04798469)
DESCRIPTION:testosterone undecanoate\, phase 2\, Hypogonadism.\nStudy: Pain
  Alleviation With Testosterone in Opioid-Induced Hypogonadism\nEstimated p
 rimary completion: 30 September 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/testosterone-undecanoate#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04798469
URL:https://assetmemo.bio/drug/testosterone-undecanoate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03910738-6672@assetmemo.bio
DTSTAMP:20261121T005343Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:testosterone undecanoate: Phase 2 readout est. (NCT03910738)
DESCRIPTION:testosterone undecanoate\, phase 2.\nStudy: TOTEM RRMS : TestOs
 terone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitti
 ng Multiple Sclerosis\nEstimated primary completion: December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/testosterone-undecanoate#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT039107
 38
URL:https://assetmemo.bio/drug/testosterone-undecanoate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06188767-6672@assetmemo.bio
DTSTAMP:20261121T005343Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:testosterone undecanoate: Phase na readout est. (NCT06188767)
DESCRIPTION:testosterone undecanoate\, phase na.\nStudy: Testosterone-induc
 ed Muscle Memory and Underlying Mechanisms\nEstimated primary completion: 
 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/test
 osterone-undecanoate#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06188767
URL:https://assetmemo.bio/drug/testosterone-undecanoate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03851627-6672@assetmemo.bio
DTSTAMP:20261121T005343Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:testosterone undecanoate: Phase 4 readout est. (NCT03851627)
DESCRIPTION:testosterone undecanoate\, phase 4\, Hypogonadism.\nStudy: Effe
 cts of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in 
 Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism\nEstimated 
 primary completion: September 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/testosterone-undecanoate#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03851627
URL:https://assetmemo.bio/drug/testosterone-undecanoate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07512323-6672@assetmemo.bio
DTSTAMP:20261121T005343Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:testosterone undecanoate: Phase 2 readout est. (NCT07512323)
DESCRIPTION:testosterone undecanoate\, phase 2.\nStudy: Effect of Testoster
 one on Elderly Frail Men With Testosterone Deficiency\nEstimated primary c
 ompletion: 30 September 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/testosterone-undecanoate#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07512323
URL:https://assetmemo.bio/drug/testosterone-undecanoate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
